Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 216

1.

Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics.

Coplan PM, Kale H, Sandstrom L, Landau C, Chilcoat HD.

Pharmacoepidemiol Drug Saf. 2013 Dec;22(12):1274-82. doi: 10.1002/pds.3522. Epub 2013 Sep 30.

2.

Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010.

Severtson SG, Bartelson BB, Davis JM, Muñoz A, Schneider MF, Chilcoat H, Coplan PM, Surratt H, Dart RC.

J Pain. 2013 Oct;14(10):1122-30. doi: 10.1016/j.jpain.2013.04.011. Epub 2013 Jun 29.

PMID:
23816949
3.

The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers.

Havens JR, Leukefeld CG, DeVeaugh-Geiss AM, Coplan P, Chilcoat HD.

Drug Alcohol Depend. 2014 Jun 1;139:9-17. doi: 10.1016/j.drugalcdep.2014.02.018. Epub 2014 Feb 26.

PMID:
24721614
4.

Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation.

Sessler NE, Downing JM, Kale H, Chilcoat HD, Baumgartner TF, Coplan PM.

Pharmacoepidemiol Drug Saf. 2014 Dec;23(12):1238-46. doi: 10.1002/pds.3658. Epub 2014 Jun 11.

5.

Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse.

McNaughton EC, Coplan PM, Black RA, Weber SE, Chilcoat HD, Butler SF.

J Med Internet Res. 2014 May 2;16(5):e119. doi: 10.2196/jmir.3397.

6.

Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone.

Severtson SG, Ellis MS, Kurtz SP, Rosenblum A, Cicero TJ, Parrino MW, Gilbert MK, Buttram ME, Dasgupta N, BucherBartelson B, Green JL, Dart RC.

Drug Alcohol Depend. 2016 Nov 1;168:219-229. doi: 10.1016/j.drugalcdep.2016.09.018. Epub 2016 Oct 3.

7.

Use of prescription opioids with abuse-deterrent technology to address opioid abuse.

Michna E, Kirson NY, Shei A, Birnbaum HG, Ben-Joseph R.

Curr Med Res Opin. 2014 Aug;30(8):1589-98. doi: 10.1185/03007995.2014.915803. Epub 2014 Apr 24.

PMID:
24738694
8.

The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.

Coplan PM, Chilcoat HD, Butler SF, Sellers EM, Kadakia A, Harikrishnan V, Haddox JD, Dart RC.

Clin Pharmacol Ther. 2016 Sep;100(3):275-86. doi: 10.1002/cpt.390. Epub 2016 Jun 22. Erratum in: Clin Pharmacol Ther. 2017 Apr;101(4):541.

9.

Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.

Cicero TJ, Ellis MS.

JAMA Psychiatry. 2015 May;72(5):424-30. doi: 10.1001/jamapsychiatry.2014.3043.

PMID:
25760692
10.

Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin).

Chilcoat HD, Coplan PM, Harikrishnan V, Alexander L.

Drug Alcohol Depend. 2016 Aug 1;165:221-8. doi: 10.1016/j.drugalcdep.2016.06.009. Epub 2016 Jun 16.

11.

Impact of abuse-deterrent OxyContin on prescription opioid utilization.

Hwang CS, Chang HY, Alexander GC.

Pharmacoepidemiol Drug Saf. 2015 Feb;24(2):197-204. doi: 10.1002/pds.3723. Epub 2014 Nov 13.

PMID:
25393216
12.

Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene.

Larochelle MR, Zhang F, Ross-Degnan D, Wharam JF.

JAMA Intern Med. 2015 Jun;175(6):978-87. doi: 10.1001/jamainternmed.2015.0914.

PMID:
25895077
13.

Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.

Degenhardt L, Larance B, Bruno R, Lintzeris N, Ali R, Farrell M.

Addiction. 2015 Feb;110(2):226-37. doi: 10.1111/add.12746. Epub 2014 Oct 30.

PMID:
25358480
14.

Trends in analgesic exposures reported to Texas Poison Centers following increased regulation of hydrocodone.

Haynes A, Kleinschmidt K, Forrester MB, Young A.

Clin Toxicol (Phila). 2016 Jun;54(5):434-40. doi: 10.3109/15563650.2016.1148720. Epub 2016 Feb 26.

PMID:
26919555
15.
16.

Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US.

Rossiter LF, Kirson NY, Shei A, White AG, Birnbaum HG, Ben-Joseph R, Michna E.

J Med Econ. 2014 Apr;17(4):279-87. doi: 10.3111/13696998.2014.897628. Epub 2014 Mar 7.

PMID:
24559196
17.

Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential.

Sellers EM, Perrino PJ, Colucci SV, Harris SC.

J Psychopharmacol. 2013 Sep;27(9):808-16. doi: 10.1177/0269881113493364. Epub 2013 Jun 19.

PMID:
23784739
18.

Comparison of abuse, suspected suicidal intent, and fatalities related to the 7-day buprenorphine transdermal patch versus other opioid analgesics in the National Poison Data System.

Coplan PM, Sessler NE, Harikrishnan V, Singh R, Perkel C.

Postgrad Med. 2017 Jan;129(1):55-61. doi: 10.1080/00325481.2017.1269596. Epub 2016 Dec 21.

PMID:
27922764
19.

Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.

Gudin J, Levy-Cooperman N, Kopecky EA, Fleming AB.

Pain Med. 2015 Nov;16(11):2142-51. doi: 10.1111/pme.12834. Epub 2015 Jun 22.

PMID:
26108255
20.

Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users.

Harris SC, Perrino PJ, Smith I, Shram MJ, Colucci SV, Bartlett C, Sellers EM.

J Clin Pharmacol. 2014 Apr;54(4):468-77. doi: 10.1002/jcph.235. Epub 2013 Dec 11.

Supplemental Content

Support Center